Human Reproduction (journal)

Gattaca Genomics Appoints Dr. Tyl Taylor as New Director of Genetics Services

Retrieved on: 
Thursday, March 7, 2024
Aneuploidy, RBM, Human Reproduction (journal), Reproductive medicine, Genetics, REACH, IVF, Associate, Society, Abstract, Genetic testing, Knowledge, Genomics, Management

Florida, March 06, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics, a leading name in genetic services, appoints Dr. Tyl Taylor as its new Director of Genetics Services.

Key Points: 
  • Florida, March 06, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics, a leading name in genetic services, appoints Dr. Tyl Taylor as its new Director of Genetics Services.
  • Dr. Taylor brings a wealth of experience and expertise in the field, making him a valuable addition to the Gattaca team.
  • In his role as the Director of Genetics Services at Gattaca, Dr. Taylor is poised to lead the team towards new heights in genetic research and reproductive technologies.
  • We are confident that under his guidance, Gattaca will continue to drive advancements in genetic services," said Michael Carbonara, CEO of Gattaca Genetics.

Fertility Expert Dr. Banafsheh Kashani Shares Advice for Couples Trying to Conceive this Holiday Season

Retrieved on: 
Thursday, November 30, 2023
Other Health, Practice Management, Physical Therapy, Managed Care, Other Consumer, General Health, Women, Parenting, Men, Fitness & Nutrition, Children, Baby, Maternity, Family, Vitamins, Supplements, Consumer, Health, Well, Holiday, Stress management, Nutrition, Folate, Woman, Pressure, Menstrual cycle, Antioxidant, Human Reproduction (journal), Infertility, Meditation, Nutrient, Communication, Human, Reproduction, Survival, CDC, Mindfulness, FIRST, Knowledge, Empathy, Tourism, Birth control

Banafsheh Kashani , M.D., double board-certified OB-GYN, reproductive endocrinologist, and infertility specialist, offers expert guidance for couples embarking on the journey of conception during this time.

Key Points: 
  • Banafsheh Kashani , M.D., double board-certified OB-GYN, reproductive endocrinologist, and infertility specialist, offers expert guidance for couples embarking on the journey of conception during this time.
  • "The holidays are a popular time for couples to begin their journey of trying to conceive, but there can be added pressure, especially if dealing with infertility,” said Dr. Kashani.
  • "To navigate this process successfully, couples should start by seeking knowledge and resources to ensure they have the most accurate and helpful information.”
    Dr. Kashani offers insights for couples trying to conceive during the holidays, from nutrition and stress management to products to consider.
  • Stress Management: Navigate the holiday hustle with effective strategies to minimize stress and create a fertility-friendly environment.

Fertilix Proven Effective in Blocking Damage From Low-Dose Exposure to Chemicals Commonly Found in Plastic Consumer Products

Retrieved on: 
Thursday, May 18, 2023
Male, DNA, Biotechnology, ESHRE, Pollution, Microplastics, Fertility clinic, Dibutyl phthalate, Risk, Fertility, Human Reproduction (journal), AF, European Society of Human Reproduction and Embryology, Health, Reproductive endocrinology and infertility, Female, Dietary supplement, Antioxidant, Embryology

The study, led by Professor Joel Drevet, examined two common chemicals widely used in the plastic industry: dibutyl phthalate and bisphenol AF.

Key Points: 
  • The study, led by Professor Joel Drevet, examined two common chemicals widely used in the plastic industry: dibutyl phthalate and bisphenol AF.
  • These chemicals have long been linked to lowering male fertility, but the novelty of this study was in evaluating doses that were previously considered safe or inconsequential for consumers.
  • Interestingly, the study also showed that co-administration with micronutrient supplement Fertilix(R) significantly blocked the damaging effects of these chemicals on sperm DNA.
  • This study is now available with open-access in Antioxidants, a premier journal in antioxidant research, and can be downloaded here.

Ovation Research Included in Four Abstracts Selected for Presentation at ESHRE 2023

Retrieved on: 
Thursday, June 29, 2023
University of Adelaide, Wing, Partnership, ESHRE, Intelligence, Research, Doctor of Philosophy, Ovation, IVF, Fertility, Science, Patient, University, Selangor, Embryology, Annual general meeting, Human Reproduction (journal), Hospital, European Society of Clinical Microbiology and Infectious Diseases, Reproduction, Reproductive endocrinology and infertility, Outline of physical science, Nightclub, Medical device

Nashville, June 29, 2023 (GLOBE NEWSWIRE) -- Ovation® Fertility scientists contributed to four pieces of research accepted for poster presentation at the ESHRE virtual 39th Annual Meeting.

Key Points: 
  • Nashville, June 29, 2023 (GLOBE NEWSWIRE) -- Ovation® Fertility scientists contributed to four pieces of research accepted for poster presentation at the ESHRE virtual 39th Annual Meeting.
  • The event, hosted by the European Society of Human Reproduction and Embryology, was held this year in Copenhagen, Denmark, June 25-28, 2023.
  • “The Ovation scientific team is incredibly excited about the opportunity to present our collaborative efforts and works in Copenhagen this year,” says Ovation Vice President of Scientific Advancement Matthew “Tex” VerMilyea, PhD, HCLD/CC.
  • Ovation recently joined US Fertility, the nation’s largest partnership of physician-owned fertility practices, to create the leading fertility platform in the United States.

Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program

Retrieved on: 
Tuesday, June 27, 2023
Research, Women, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Science, Other Science, Injection, Male, Inc., Pregnancy, FSHR, Drug development, ESHRE, Ovulation, Woman, Infertility, Polycystic ovary syndrome, Life expectancy, Solubility, Drug design, IVF, FSH, CDC, Protein, GPCR, Publication, PCOS, Fertility, Human Reproduction (journal), European Society of Gynaecological Oncology, AMHR2, Reproductive endocrinology and infertility, TSHR, Egg, Pharmaceutical industry, Birth control, Embryology

Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.

Key Points: 
  • Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.
  • Therefore, a successful oral FSHR drug must stimulate the FSH receptor without stimulating the thyroid hormone receptor (TSHR).
  • Early Celmatix data suggests that their unique, rationally designed compounds overcome this significant hurdle to drug development for this target.
  • Celmatix Chief Scientific Officer, Dr. Stephen Palmer, notes, “We are very pleased to see that several of our novel compounds demonstrate the desired potency and selectivity required for a successful oral FSH drug.

Fairtility Unveils CHLOE OQ™ Expanding its Offering into Fertility Preservation

Retrieved on: 
Monday, June 26, 2023
CE, Pregnancy, ESHRE, Life, Oocyte, Woman, Fertilisation, Fertility clinic, IVF, Egg donation, TEL, Fertility preservation, Patient, Fertility, Biology, Human Reproduction (journal), Entrepreneurship, European Society of Human Reproduction and Embryology, Reproduction, Myllocerus discolor, Pregnancy rate, Egg, Mineral oil, Medical device

TEL AVIV, Israel, June 26, 2023 /PRNewswire/ -- Fairtility, the transparent AI innovator powering reproductive care for improved outcomes, today announced the launch of CHLOE OQ™, bringing Oocyte Quality Insights to CHLOE's core technology suite of capabilities and expanding the applicability of its AI-driven decision support tool to fertility preservation. The solution will be unveiled at the 39th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) being held in Copenhagen, Denmark from June 25 to 28, 2023.

Key Points: 
  • With CE declared for CHLOE OQ™, the new Oocyte Quality Insights capability offers IVF professionals comprehensive information to support decision making as patients undergo fertility preservation or assisted reproductive journeys.
  • However, assessing oocyte quality has remained a statistical gamble," said Dr. Cristina Hickman, Chief Clinical Officer of Fairtility.
  • Egg Donation: CHLOE OQ helps fertility clinics and egg banks to further assess the quality of donor eggs, ensuring equitable distribution to recipients.
  • CHLOE OQ now provides decision support for fertility preservation, egg donation, and female-factor infertility in IVF treatment.

Instituto Bernabeu creates the first AI International Unit applied to Reproductive Medicine

Retrieved on: 
Wednesday, June 7, 2023
Male, Pregnancy, IB Group 3 subjects, ESHRE, International unit, Woman, Infertility, Prognosis, Medicine, Research, Multimedia, Fertilisation, Reproduction, Patient, Child, Fertility, Artificial intelligence, Human Reproduction (journal), Knowledge, Diagnosis, AI, European Society of Human Reproduction and Embryology, Congress, Reproductive medicine, Gynaecology, Reproductive endocrinology and infertility, Egg, Medical device, Embryology

After a recognized research trajectory in the use of Artificial Intelligence, Instituto Bernabeu has just created the first International Unit specialized in AI applied to Reproductive Medicine.

Key Points: 
  • After a recognized research trajectory in the use of Artificial Intelligence, Instituto Bernabeu has just created the first International Unit specialized in AI applied to Reproductive Medicine.
  • "This world-first unit is the result of our Scientifics successful work in the AI field in recent years.
  • Thanks to AI, these patients' diagnosis and prognosis will significantly improve", points out the IB Group's medical co-director Andrea Bernabeu.
  • Among the members of this new unit, highly skilled and renowned specialists in the different areas stand out: Instituto Bernabeu Mallorca medical director, Dr. Jordi Suñol; Instituto Bernabeu Group Embryology Unit director, Dr. Jorge Ten; Congenital Defects Unit director, the biochemist Dr. José Antonio Ortiz; and Instituto Bernabeu Madrid Embryology director, Leyre Herrero.

CCRM Fertility Expands its Services With World-Class Reproductive Urology Care Addressing Growing Need for Sperm-Related Fertility Treatment

Retrieved on: 
Thursday, June 1, 2023
Male, Partnership, Pregnancy, TESE, Semen analysis, Infertility, Research, Meta-analysis, Human, Science, Fertility, Fertility preservation, Descendant, Patient, Human Reproduction (journal), Health, Reproduction, Birth control

DENVER, June 1, 2023 /PRNewswire/ -- CCRM Fertility, the global pioneer in fertility treatment, research and science, is now offering world-class reproductive urology care to provide integrated and comprehensive fertility care to men, those who were assigned male at birth and their partners. A meta-analysis published in Human Reproduction found that sperm counts have declined 50% in just 40 years. By offering high-quality urology care in-house, CCRM Fertility can better address the growing need for sperm-related fertility treatment and modernize how individuals and couples can access reproductive urology experts and resources to improve their chances of a successful pregnancy.

Key Points: 
  • By offering high-quality urology care in-house, CCRM Fertility can better address the growing need for sperm-related fertility treatment and modernize how individuals and couples can access reproductive urology experts and resources to improve their chances of a successful pregnancy.
  • "By having high-quality male and fertility care and services under one roof, we can accelerate the fertility journey helping to improve sperm parameters and success rates."
  • "We're excited to now offer high-quality reproductive urology care at CCRM Fertility network clinics," CCRM Fertility CEO Bob Lagalia.
  • To learn more about CCRM Fertility reproductive urology services and participating clinics, visit ccrmivf.com .

India's most advanced and largest IVF clinic group, Indira IVF, will offer all patients Artificial Intelligence technology to improve pregnancy outcomes

Retrieved on: 
Monday, October 24, 2022
Online, SAN, ESHRE, Genetics, Sale, Health care, Social network, American Society for Reproductive Medicine, Women's health, Reproductive medicine, Society, Patient, Privacy, Publication, Workforce, Multimedia, Infertility, Taboo, Human Reproduction (journal), European Society for Primary Immunodeficiencies, Technology, Partnership, AI, Scientific Reports, CEO, International business, IVF, Artificial intelligence, Fertility, TA Associates, ASRM, Pregnancy, Ownership, Medical device, Mineral oil, Embryology

SAN FRANCISCO, Oct. 24, 2022 /PRNewswire/ -- The largest and most advanced IVF clinic group in India, Indira IVF, will be rolling out the latest in Artificial Intelligence technology across their 100+ clinics in India in November 2022.

Key Points: 
  • SAN FRANCISCO, Oct. 24, 2022 /PRNewswire/ -- The largest and most advanced IVF clinic group in India, Indira IVF, will be rolling out the latest in Artificial Intelligence technology across their 100+ clinics in India in November 2022.
  • Life Whisperer Viability assesses how likely an embryo is to lead to a pregnancy, and Life Whisperer Genetics non-invasively assesses embryo genetic integrity.
  • Life Whisperer is currently authorized for sale in over 40 countries worldwide, with India as a key market.
  • Life Whisperer aims to improve IVF success rates at every point and, as a result, reduce time-to-pregnancy, making IVF more affordable and accessible to patients globally.

Fairtility Launches AI Academy to Demystify Use of Artificial Intelligence in Fertility Care

Retrieved on: 
Tuesday, July 26, 2022
Gynaecology, Knowledge, Education, Clinical research, Ben-Gurion University of the Negev, Industry, Obstetrics, Twitter, Ethics, CEO, Annual general meeting, Infertility, Human Reproduction (journal), University Medical Center Schleswig Holstein, Associate, ESHRE, Engineering, Weill Cornell Medical College in Qatar, Adoption, European Society for Primary Immunodeficiencies, Bachelor of Engineering, Technology, Information system, LinkedIn, Patient, Reproductive medicine, Digital health, Department, IVF, Entrepreneurship, Health care, TEL, Medical device, Fertility, Software, AI, Embryology

TEL AVIV, Israel, July 26, 2022 /PRNewswire/ -- Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced the launch of the AI Academy, a new educational platform that will host healthcare and technology experts to engage the IVF community in the conversation around the responsible adoption of AI innovation in IVF care. 

Key Points: 
  • Fairtility launched the AI Academy at the European Society of Human Reproduction and Embryology (ESHRE) 38th Annual Meeting, which took place in Milan, Italy, July 3-6.
  • Dr. Gerard Letterie, a leader in reproductive endocrinology and infertility specialist at Seattle Fertility, serves as the Academic Head of the AI Academy.
  • "Our goal with the AI Academy is to provide the needed education, bringing IVF professionals into the conversation on AI transformation for fertility care.
  • For further information or to register for AI Academy, visit: www.fairtility.com/AIAcademy
    Fairtility is powering in vitro fertilization (IVF) through transparent AI to improve outcomes.